Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2018 16:01 ET | Source: AveXis, Inc.

AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients

CHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
January 22, 2018 16:05 ET | Source: AveXis, Inc.

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CHICAGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock at...
January 16, 2018 20:18 ET | Source: AveXis, Inc.

AveXis Announces Pricing of Public Offering of Common Stock

CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering...
January 16, 2018 07:25 ET | Source: AveXis, Inc.

AveXis Announces Proposed Public Offering of Common Stock

CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common...
January 16, 2018 07:20 ET | Source: AveXis, Inc.

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

– Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of AVXS-101 in...
January 08, 2018 08:00 ET | Source: AveXis, Inc.

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMAAmended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s...
January 04, 2018 16:00 ET | Source: AveXis, Inc.

AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

– Company to submit information requested by FDA to the IND on an on-going basis – – AveXis plans to request a pre-BLA meeting in Q2 2018 – – Conference call and webcast today at 4:30 pm EST – ...
December 13, 2017 16:00 ET | Source: AveXis, Inc.

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

– The FDA notified AveXis it may initiate the Phase 1 trial in SMA Type 2 based on a review of data provided by the company; trial to commence immediately – – The trial will evaluate...
November 09, 2017 16:00 ET | Source: AveXis, Inc.

AveXis Reports Third Quarter 2017 Financial and Operating Results

– First patient has been dosed in pivotal trial of AVXS-101 for SMA Type 1 – – Conference call and webcast November 9 at 4:30 p.m. EST – CHICAGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc....
November 02, 2017 08:00 ET | Source: AveXis, Inc.

AveXis to Report Third Quarter 2017 Financial and Operating Results

CHICAGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...